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Abstract: Dengue Hemorrhagic Fever (DHF) patients in Indonesia reached 129,650 cases 
with a death toll of 1,071 people in 2015. DHF puts an economic burden on the community 
and government. This study aims to determine the difference in real cost tariffs and INA 
CBG's for DHF in a hospital in Sidoarjo, East Java. This cross-sectional study applied a 
descriptive design, conducted from January to December 2019. The data in this study 
consisted of characteristic data and differences in real hospital tariffs and INA CBG tariffs 
for DHF in the hospital treatment room. 625 hospitalized cases were included in this study. 
This hospital underwent a deficit (loss) of 30% from the difference between the total INA 
CBG's package tariffs and the total real hospital tariffs in 2019. There is a negative 
difference between the real hospital tariffs and the tariffs according to INA CBG's in the 
treatment of dengue fever in a hospital in Sidoarjo which produces losses for the hospital. 




The World Health Organization (2011) states that the world's population is estimated at 
2.5-3 billion at risk of contracting dengue haemorrhagic fever (DHF), especially those living 
in urban areas in tropical and subtropical countries (Organization, 2011). Dengue infections 
worldwide reach 50 million every year. In Southeast Asia, it is estimated that there are as 
many as 100 million cases of dengue fever and 500,000 cases of dengue that require hospital 
treatment and around 25,000 deaths in Southeast Asia for dengue disease reach 5% annually 
(Bedouch et al., 2012). 
By the Strategic Plan of the Ministry of Health of the Republic of Indonesia, strategic 
targets in Health Development for 2015-2019 include reducing morbidity due to infectious 
diseases, by increasing the percentage of districts/cities with Dengue Haemorrhagic Fever 
(DBD) morbidity rate of ≤49 per 100,000 populations (Moll et al., 2011). It is targeted that in 
2017 it will be at least 64%, in 2018 it will be at least 66% and in 2019 it is expected that at 
least 68% of districts/cities will have a dengue fever rate of ≤ 49 per 100,000 populations. 
Dengue haemorrhagic fever is still a world public health problem, especially in tropical and 
subtropical regions, including Indonesia as one of the dengue-endemic countries (Haryanto et 
al., 2014). Since the first time DHF cases were reported in Indonesia in 1968 in Jakarta and 
Surabaya, the DHF morbidity rate has shown an increasing trend from year to year and the 
area of its spread has become wider in almost all districts/cities in Indonesia (Noisakran and 
Perng, 2008). However, the death rate due to dengue in the last decade has been reduced to 
below 1%. 
The high incidence of dengue fever can cause an increment in the health budget, 
especially the cost of drugs and medical consumables during hospitalization. The government 
budget is limited, so it is necessary to choose the use of drugs by taking into account quality 
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and cost control, as well as the study of pharmacological aspects in the selection and use of 
drugs effectively and efficiently in analyzing drug costs (Shander et al., 2010; Syakur, 2018). 
The medical expenses incurred in the JKN era are matters that need to be considered 
because the determination of real hospital cost tariffs is designed so that the hospital does not 
suffer losses for any actions given by the hospital to patients which include operational costs, 
maintenance, development, and improvement of service quality (Suaya et al., 2009; Syakur et 
al., 2020a) which exists. The real costs also include hospital service tariffs such as hospital 
services, medical services, therapeutic services, laboratory tests, anaesthesia, use of medical 
materials and devices, so that it is hoped that a balance can occur between an increase in real 
costs and an increase in services received by patients and the patient's ability to pay for these 
costs. 
The role of the pharmaceutical industry in the health sector is one of the most important 
pieces for society because the pharmaceutical industry is a partner of the government to 
improve public health (Syakur et al., 2020b). With this JKN program, if it is not managed 
properly, it will create losses to the Pharmaceutical Industry due to low costs and low 
margins, besides that, it can also cause losses to hospitals if drug administration is not 
effective and efficient. Hence the role of pharmacists in the selection of effective and 
efficient therapies as well as rational treatment is needed because the form of procurement of 
drugs and medical devices, especially pharmaceuticals, refers to the three main aspects of 
health insurance, namely easy access (accessibility), affordable prices and logical use of 
drugs (rational). Drug procurement in the JKN era is one of the most important components 
including medical expenses so that to achieve the objectives of this government program, the 
availability of drugs is of the utmost importance for the program's success (Shander et al., 
2010; Suaya et al., 2009)  
In this research, the average real cost of direct medical costs was calculated, so that the 
goal of this study was to ascertain whether there was a difference from the  real costs 
incurred by the Hospital for Dengue Fever Patients for JKN-BPJS participants, with the real 
costs received by the hospital INA CBG's JKN-BPJS package tariffs. 
 
II. Research Method 
 
This research was conducted with a cross-sectional study design utilizing a descriptive 
design. Data collection was carried out retrospectively in class I, II, and III care rooms and in 
the case-mix room of a hospital in Sidoarjo from January to December 2019 with the number 
of research subjects using total sampling. The population was all DHF patients who were 
treated at a hospital in Sidoarjo with funding using the BPJS from January to December 2019. 
The research subjects were part of the population that met the inclusion criteria, namely 
dengue fever patients with complete medical record data, undergoing treatment in a hospital 
in Sidoarjo, using BPJS coverage. Patients who did not meet the inclusion criteria were 
excluded from the study. The materials used in the study were medical records of patients 
diagnosed with dengue fever. 
Hospital tariffs are the total costs incurred by patients while undergoing treatment at the 
hospital in the form of administrative costs, accommodation, nursing care, transfusion 
measures, doctor examinations, supporting examinations, medicines, and medical devices as 
well as consumable medical items.  
The data in this study are data obtained from characteristic data and data on disparities 
between real tariffs and INA CBG tariffs. Demographic data in this study are age, gender, 
class of care, and length of stay (LOS). All data were analyzed using SPSS version 23 and 










There were 625 inpatient cases of dengue fever patients who were included in the 
study with data on the characteristics of research subjects in Table 1 which shows that the 
number of male subjects was higher than women, namely 345 (55.2%) while women were 
280 (44.8%). This condition was observed in the mild dengue fever as many as 405 cases 
(64.8%), followed by severe dengue fever as many as 201 cases (32.16%) and moderate 
dengue fever as many as 19 cases (3.04%). 
The total real tariff for one year for dengue fever cases is Rp. 2,737,682,647. This 
figure is obtained from 625 hospitalized cases, most of which consist of 277 young adults 
(aged 14-28 years) so it can be estimated that each young adult is the average cost of Rp. 
1,213,340,949 per year. Throughout 2019, a hospital in Sidoarjo received a negative value 
of Rp. 821,193,747 (-30%) of the difference between the total INA CBG package tariff 
and the total real tariff spent by the hospital, as shown in Table 2. 
The incidence of this deficit is classified based on the severity of the disease, class of 
care, and length of stay as presented in Table 3, it can be observed that the highest deficit 
incidence is 76% in patients with mild dengue fever and class 3 patients. the deficit 
occurred at treatment over 5 days. 
The average cost during hospitalization consists of expenses for non-surgical 
procedures, consultations, experts, nursing, support, radiology, laboratories, 
accommodation rooms, medicines, medical devices, consumable medical items, and 
equipment rental which are detailed in Table 4. 
 




Gender Women 280 
Men 345 
Age < 14 Years 187 
14-28 Years 277 
29-43 Years 95 
> 44 Years 66 
DF severity Mild 405 
Moderate 19 
Severe 201 
Class of Care 1 93 
2 252 
3 280 
LOS < 5 Days 257 
> 5 Days 368 















Table 2. Difference between Total Hospital Real Tariffs and INA CBG's Real Tariffs 
Total Real 
Hospital Tariffs 






IDR          
2.737.682.647 
IDR          
1.916.488.900 




Table 3. Incidence of Deficits According to Severity, Class of Care and Length of Stay 
 
Deficit n (%) No Deficit n (%) Total 
Severity           
Mild DHF 395 76% 10 10% 405 
Moderate DHF 17 3% 2 2% 19 
Severe DHF 108 21% 93 89% 201 
Class of Care 
     Class 1 75 14% 18 17% 93 
Class 2 217 42% 35 33% 252 
Class 3 228 44% 52 50% 280 
Length of Stay 
     < 5 Days 190 37% 67 64% 257 
> 5 Days 330 63% 38 36% 368 
      
 
Table 4. Details of Hospital Tariffs 
Type of Fee  Average  
Non-Surgical Procedures  IDR          2.562.645 
Consultation  IDR                76.444  
Expert  IDR                   6.192  
Nursing  IDR                69.790 
Support  IDR                   3.754  
Radiology  IDR                   5.528  
Laboratorium  IDR                72.646  
Accommodation Room  IDR              227.240  
Drug  IDR                65.973  
Medical Devices  IDR                50.121  
Consumable Medical 
Materials  IDR                16.702  
Rental Tools  IDR                   6.219  



















Most of the cases of dengue fever who were hospitalized in a hospital in Sidoarjo 
were men (55.2%), this is similar to the study at Buleleng Hospital in 2013, where DHF 
patients were mostly male (51%). When compared with women which were only 49%. 
However, it is different from the research conducted by Wijayanti, et al, which states that 
most of the Jamkesmas in patients are women with a percentage of 56.02%. The highest 
age range for dengue fever patients is the age group 14-27 years (44.32%). This is different 
from the research of Wijayanti, et al which states that the highest age group of inpatients is 
40-49 years old (16.87%) which is also different from the research conducted by Djati, et 
al, which states that the age group <12 years is the highest age group for dengue fever 
because it has weaker humoral immune system function compared to the cellular immune 
system and the immune system possessed by the adult age group. Data from Infodatin 
(Ministry of Health, 2016) shows the incidence of DHF occurs mostly in adulthood, 
although the incidence of DHF does not depend on age. This result is also in accordance 
with the distribution data in Indonesia for 2012-2015 that based on gender, the number of 
men and women is not too different. 
Length of stay was assessed by extracting the duration of hospital stay measured in 
hours or days. In this study, the highest length of stay (LOS) for DHF patients was> 5 days 
(63%) compared to <5 days (37%). The average length of stay for DHF patients was 5.3 
days. The results of other studies stated that in 8 countries in America and Asia, the 
average illness period of DHF patients was 11 days, with an average fever duration of 6 
days (Banggai et al., 2019; Noisakran and Perng, 2008). 
From Table 2 it is discovered that there is a difference of 30% between the real tariff 
and the INA CBG tariff. This is in accordance with research from Suratni, et al, which 
states that in billing patient payments with National Health Insurance (JKN) for cases of 
dengue fever, the hospital casemix team reports that 60% of the bill exceeds INA CBG's 
tariffs. This research, particularly that they both find differences between the application of 
real tariffs and package tariffs (Katmini and Syakur, 2020; Nopianto et al., 2012). 
Meanwhile, according to (Nopianto et al., 2012) the factors that influence the difference in 
tariffs include the inflation component of hospital costs, government policies, third party 
payments (insurance), and health workers themselves.  
Table 3 explicates that the incidence of deficits occurs in a long length of stay (LOS) 
(> 5 days), namely 63%. This can be caused by secondary diagnoses that boost the degree 
of severity so that it can add to the diagnosis code and procedures of the secondary 
diagnosis can increase INA-CBGs tariffs (Polyzos et al., 2013; Syakur et al., 2020b). This 
is not per the statement from the BPJS as the organizer of JKN in Indonesia which claims 
that at the beginning of the implementation of the INA CBG's package, around 94 
hospitals claimed to have a surplus with INA CBG's financing costs compared to the old 
tariffs, such as the Islamic Hospital (RSI) in Surabaya. INA CBG tariffs received by the 
hospital which are low compared to the real tariffs issued by the hospital will result in the 
hospital experiencing losses. 
The longer the patient is treated, the higher the cost will be because the length of stay 
is calculated at the real tariff per day, whereas in INA CBGs the standard tariffs have been 
decided according to the actual diagnostic and procedure codes. (Alhamda and Barlian, 
2019) states that by reducing patient length of stay, the cost for CBG can be reduced (Zhuo 
et al., 2013). This is supported by the opinion of Alhamda and Barlian (2009) who saw 
from the medical aspect that with a longer length of stay, the quality of medical 









economic point of view for real tariffs, the longer the stay, the higher the fees paid by the 
payer and received by the hospital, whereas this does not apply to INA CBGs tariffs which 
are not affected by the length of stay. So that if the hospital can regulate the provision of 
health services in terms of length of stay effectively and efficiently, it will increase the 
chance of a good difference (surplus) between the real tariffs and INA CBG's tariffs. 
In Table 4, it can be seen that the largest cost component is for non-surgical 
procedures that have been adjusted to the clinical pathway at the hospital. This is following 
the statement in the Jamkesmas Implementation Guidelines for the Centre for Health 
Financing and Insurance, the Ministry of Health (2013 and 2016) which states that the cost 
of medical services/service fee is determined by the Hospital Director at a maximum of 
44% of the cost of health services provided. The medical services/service fee include fees 
for service providers in the framework of observation, diagnosis, treatment, medical 
action, treatment, consultation, visit, and/or other medical services, as well as for 




There is a negative difference between the real hospital tariffs and the INA CBG 
tariffs in cases of dengue fever in a private hospital in Sidoarjo, causing losses for the 
hospital. Additional analytical research is needed to analyse the cost of treating dengue 
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